Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Smith 353, Boston, MA, 02215, United States.
The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent FDA approval of two first-in-class proof of concept immunotherapies (sipuleucel-T and ipilimumab) has stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies that have garnered the most interest are the therapeutic vaccination strategies exemplified by sipuleucel-T and PROSTVAC-VF, and immune checkpoint blockade of CTLA-4 and PD-1. Improved understanding of the immune responses generated by these strategies and development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide building blocks for future immunotherapies.
Written by:
May KF Jr, Gulley JL, Drake CG, Dranoff G, Kantoff PW. Are you the author?
Reference: Clin Cancer Res. 2011 Jun 23. Epub ahead of print.
doi: 10.1158/1078-0432.CCR-10-3402
PubMed Abstract
PMID: 21700764
UroToday.com Prostate Cancer Section
